LEHI, Utah and LOUISVILLE, Ky., Aug. 25, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, today announced it earned multiple Gold Stevie® Awards in the 2025 International Business Awards®, including Healthcare Company of the Year and Top-Ranked AI Software Platform for Waystar AltitudeAI™. Waystar's Auth Accelerate solution also received top honors for advancing prior authorization automation with breakthrough innovation and proven client impact.
The U.S. healthcare industry incurs more than $440 billion in administrative costs annually, with claim denials and prior authorizations among the most resource-intensive challenges. Waystar's pervasive use of AI across its platform is transforming these processes, driving automation, accuracy, and results at scale.
In 2025, Waystar launched Waystar AltitudeAI™, a comprehensive suite of AI-powered capabilities that elevate productivity and accuracy in healthcare payments. In Denial and Appeal Management, Waystar AltitudeAI™'s industry-first capabilities have driven a 70% increase in appeal productivity and double-digit improvements in overturn rates, freeing capacity equal to nearly 10 full-time employees for a mid-size health system. Waystar also advanced its growth and AI strategy with a definitive agreement to acquire Iodine Software, a leader in AI-powered clinical intelligence, reinforcing its mission to simplify healthcare payments.
Waystar also debuted Auth Accelerate in 2025, which earned multiple recognitions for innovation and client outcomes. Addressing the more than two billion prior authorizations occurring annually, the solution automates end-to-end submissions and achieves industry-leading auto-approval rates of over 90%. For providers, this efficiency is equivalent to the capacity of more than a dozen full-time employees.
"Waystar is honored to receive top distinctions for technology leadership in AI transformation," said Matt Hawkins, Chief Executive Officer of Waystar. "With innovations like Waystar AltitudeAI™ and Auth Accelerate, we show how AI and advanced automation deliver strong ROI in healthcare—empowering providers to redirect resources toward patient care."
The Stevie® Awards, judged by more than 250 executives worldwide from a record 3,800 nominations, add to Waystar's growing national recognition. Recent accolades include Forbes' Most Trusted Companies in America, MedTech Breakthrough's top healthcare payments software platform, and two Best in KLAS® honors.
The International Business Awards are the world's premier business awards program. All individuals and organizations worldwide, including public and private, for-profit and non-profit, large and small, are eligible to submit nominations. The 2025 International Business Awards received nominations from organizations and individuals in 78 nations and territories.
About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.
Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$37.06 |
Daily Change: | 1.16 3.23 |
Daily Volume: | 1,280,595 |
Market Cap: | US$6.460B |
July 30, 2025 July 23, 2025 April 30, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load